⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Global Lightweight Materials Market Size, Share, Trends, and Forecast, 2026-2031 | EV and Aerospace Demand to Drive 8.72% CAGR, Reaching $354.33 Billion
globenewswire.com
AA
AL
F
PCAR
GD
BA
LMT
RTX
NOC
HXL
AVAV
ADI
TXN
NVDA
AMD
INTC
MSFT
AMZN
GOOGL
IBM
GE
CAT
DE
MMM
DD
ALGN
XRAY
MRNA
PFE
JNJ
BIIB
GILD
REGN
VRTX
AMGN
BMY
ABBV
LLY
TSLA
NIO
RIVN
LCID
GM
STLA
HMC
TM
VWAGY
XPEV
LI
BYDDF
CHPT
PLUG
FCEL
SPWR
ENPH
SEDG
NEE
EXC
BEP
IRTC
RCL
CCL
NCLH
HAL
SLB
DV
BNTX
CRSP
EDIT
NTLA
XOM
CVX
COP
SBLK
ZIM
GNK
TECK
RIO
BHP
VALE
NEM
FCX
AVNT
NNDM
SSYS
CRON
TLRY
ACB
CGC
PYPL
COIN
BITF
MARA
RIOT
CLSK
PLTR
SNOW
CRWD
PANW
SMCI
EXAS
TDOC
CI
UNH
CVS
QCOM
NXPI
ON
AEHR
AMAT
LRCX
KLAC
MU
WDC
Global Drug Discovery Market (2026-2031) - AI-Driven Target Identification Accelerates Growth
globenewswire.com
NVDA
LLY
CHAI
TMO
ABBV
AMGN
AZN
BDX
BMY
CRL
JNJ
MRK
NVS
PFE
REGN
SNY
VRTX
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
prnewswire.com
LLY
Substance Use Disorder (SUD) Drug Pipeline Analysis Report 2026 | 100+ Drug Candidates, Phase II Dominance, and Long-Acting Therapies Signal Strategic Investment Opportunities
globenewswire.com
LLY
BG
ALKS
ALT
3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
globenewswire.com
NTHI
CNTB
VBIO
LLY
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
prnewswire.com
LLY
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
prnewswire.com
LLY
Rznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for Glioma
prnewswire.com
LLY
Global Drug Discovery Informatics Market (2026-2031) - Advancements in AI and Machine Learning Accelerate Growth
globenewswire.com
TMO
DSY
SRG
CTRA
IBM
INFY
CHTR
NVDA
LLY
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
prnewswire.com
LLY